vs
Side-by-side financial comparison of PATHWARD FINANCIAL, INC. (CASH) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($276.3M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). Over the past eight quarters, PATHWARD FINANCIAL, INC.'s revenue compounded faster (21.0% CAGR vs 10.6%).
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CASH vs ESPR — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $276.3M | $168.4M |
| Net Profit | $72.9M | — |
| Gross Margin | — | — |
| Operating Margin | — | 50.6% |
| Net Margin | 26.4% | — |
| Revenue YoY | — | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $3.35 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | $168.4M | ||
| Q3 25 | $186.7M | $87.3M | ||
| Q2 25 | $195.8M | $82.4M | ||
| Q1 25 | $274.8M | $65.0M | ||
| Q4 24 | $182.6M | $69.1M | ||
| Q3 24 | $179.5M | $51.6M | ||
| Q2 24 | $188.6M | $73.8M |
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | — | ||
| Q3 25 | $38.8M | $-31.3M | ||
| Q2 25 | $42.1M | $-12.7M | ||
| Q1 25 | $75.0M | $-40.5M | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $33.5M | $-29.5M | ||
| Q2 24 | $44.9M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | 50.6% | ||
| Q3 25 | 25.9% | -11.4% | ||
| Q2 25 | 24.1% | 8.6% | ||
| Q1 25 | 33.2% | -34.0% | ||
| Q4 24 | 19.8% | -6.4% | ||
| Q3 24 | 20.9% | -31.0% | ||
| Q2 24 | 27.1% | 3.5% |
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | — | ||
| Q3 25 | 20.8% | -35.9% | ||
| Q2 25 | 21.5% | -15.4% | ||
| Q1 25 | 27.3% | -62.2% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 18.7% | -57.2% | ||
| Q2 24 | 23.8% | -83.9% |
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | $0.32 | ||
| Q3 25 | $1.69 | $-0.16 | ||
| Q2 25 | $1.81 | $-0.06 | ||
| Q1 25 | $3.14 | $-0.21 | ||
| Q4 24 | $1.23 | $-0.14 | ||
| Q3 24 | $1.34 | $-0.15 | ||
| Q2 24 | $1.78 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $157.6M | $167.9M |
| Total DebtLower is stronger | $59.5M | — |
| Stockholders' EquityBook value | $850.7M | $-302.0M |
| Total Assets | $7.1B | $465.9M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | $167.9M | ||
| Q3 25 | $120.6M | $92.4M | ||
| Q2 25 | $258.3M | $86.1M | ||
| Q1 25 | $254.2M | $114.6M | ||
| Q4 24 | $597.4M | $144.8M | ||
| Q3 24 | $158.3M | $144.7M | ||
| Q2 24 | $298.9M | $189.3M |
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | $-302.0M | ||
| Q3 25 | $858.0M | $-451.4M | ||
| Q2 25 | $819.0M | $-433.5M | ||
| Q1 25 | $814.7M | $-426.2M | ||
| Q4 24 | $758.3M | $-388.7M | ||
| Q3 24 | $822.5M | $-370.2M | ||
| Q2 24 | $748.4M | $-344.2M |
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | $465.9M | ||
| Q3 25 | $7.2B | $364.0M | ||
| Q2 25 | $7.2B | $347.1M | ||
| Q1 25 | $7.0B | $324.0M | ||
| Q4 24 | $7.6B | $343.8M | ||
| Q3 24 | $7.5B | $314.1M | ||
| Q2 24 | $7.5B | $352.3M |
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | $45.2M | ||
| Q3 25 | $303.7M | $-4.3M | ||
| Q2 25 | $30.4M | $-31.4M | ||
| Q1 25 | $188.3M | $-22.6M | ||
| Q4 24 | $-71.7M | $-35.0M | ||
| Q3 24 | $143.1M | $-35.3M | ||
| Q2 24 | $113.2M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | — | ||
| Q3 25 | $300.3M | — | ||
| Q2 25 | $27.7M | — | ||
| Q1 25 | $184.7M | — | ||
| Q4 24 | $-73.8M | — | ||
| Q3 24 | $138.8M | $-35.5M | ||
| Q2 24 | $111.0M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | — | ||
| Q3 25 | 160.9% | — | ||
| Q2 25 | 14.1% | — | ||
| Q1 25 | 67.2% | — | ||
| Q4 24 | -40.4% | — | ||
| Q3 24 | 77.3% | -68.7% | ||
| Q2 24 | 58.8% | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 0.0% | ||
| Q3 25 | 1.8% | 0.0% | ||
| Q2 25 | 1.4% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.1% | 0.0% | ||
| Q3 24 | 2.4% | 0.3% | ||
| Q2 24 | 1.2% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
